Turning cold tumors into hot tumors by improving T-cell infiltration

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend on the infiltration of T cells capable of recognizing and killing tumor cells. ICIs are not effective in cold tumors, which are characterized by the lack of T-cell infiltration. To realize the full potential of immunotherapy and solve this obstacle, it is essential to understand the drivers of T-cell infiltration into tumors. We present a critical review of our understanding of the mechanisms underlying cold tumors, including impaired T-cell priming and deficient T-cell homing to tumor beds. Hot tumors with significant T-cell infiltration are associated with better ICI efficacy. In this review, we summarize multiple strategies that promote the transformation of cold tumors into hot tumors and discuss the mechanisms by which these strategies lead to increased T-cell infiltration. Finally, we discuss the application of nanomaterials to tumor immunotherapy and provide an outlook on the future of this emerging field. The combination of nanomedicines and immunotherapy enhances cross-presentation of tumor antigens and promotes T-cell priming and infiltration. A deeper understanding of these mechanisms opens new possibilities for the development of multiple T cell-based combination therapies to improve ICI effectiveness.

Automated summary

Immunotherapy, particularly through immune checkpoint inhibitors, has significantly improved the treatment of malignant tumors by enhancing T cell infiltration into tumors. Understanding the mechanisms underlying cold tumors, which lack T cell infiltration, is crucial to improving immunotherapy efficacy. Strategies to transform cold tumors into hot tumors and increase T cell infiltration are discussed, along with the potential of nanomedicines in enhancing tumor immunotherapy.